Senolytic peptide

FOXO4-DRI

FOXO4-DRI is a senolytic peptide tested in cells and mice; searches identified no human trial and no pharmacokinetic study, and the app's 1-hour half-life is a class-based estimate.1

Anecdotal evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

FOXO4-DRI after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.

Drawn from the half-life in the app's model, ~1 h. The model's figures

FOXO4-DRI is a peptide designed to disrupt the interaction between the transcription factor FOXO4 and p53 inside senescent cells.1 Its "DRI" label stands for D-retro-inverso: the authors of the founding paper describe mimicking a protein domain with D-amino acids in a reversed sequence and name the result FOXO4-DRI.1 The compound is designed to cause cell death, and the app lists it as an experimental senolytic peptide sold as a research chemical. The app grades the evidence as anecdotal.

The studies read for this entry used cultured cells and mice for FOXO4-DRI, plus one NMR structural study; the pulmonary hypertension study also used rat models and patient lung samples for senescence markers.6 The 18 PubMed records returned for "FOXO4-DRI senescent cells" were listed as journal articles or reviews, none with a clinical trial publication type. The ClinicalTrials.gov search for "FOXO4" returned one record, a lymphoma trial of celecoxib that is unrelated to the peptide, and the search for "FOXO4-DRI senolytic peptide" returned none.

The founding paper's senior author, Peter de Keizer, describes in an interview a company called Cleara that was founded to take the work towards the clinic.2 A 2025 structural study that includes de Keizer among its authors states that "This research was partly funded by Cleara Biotech" and that two of its authors hold shares in the company.3 The same statement says that B.B., E.S., P.D.K. and T.M. hold a published patent (WO/2021/165538) on compounds that bind p53, or bind p53 and inhibit its interaction with FOXO4, and that the binding and structural studies of FOXO4-DRI with p53 reported in the paper are related to the patent.3

Baar and colleagues (Cell, 2017) report that FOXO4 expression rose in cells made senescent by ionizing radiation, and that inhibiting FOXO4 in already senescent cells reduced their viability.1 They designed a cell-permeable peptide from part of the p53-interaction domain of FOXO4, fused with an HIV-TAT sequence to carry it into cells.1 In NMR competition experiments with recombinant proteins the peptide competed with FOXO4 for p53 binding; in senescent IMR90 cells, p53 knock-down reduced its effect, pan-caspase inhibitors had a similar effect, which the authors say suggests a caspase-dependent effect, and a Caspase-3/7 dye showed activation in senescent but not control cells.1 The authors observed the effect in cultured cells from 24 to 36 hours after administration.1

Bourgeois and colleagues (Nature Communications, 2025) used NMR to model the complexes, and report that the disordered FOXO4-DRI binds the disordered p53 transactivation domain "and forms a transiently folded complex".3 They also report that p53 phosphorylation increases the affinity for both FOXO4 and FOXO4-DRI.3 This is a binding study in solution; it contains no animal or human dosing.

Zhang and colleagues (Aging, 2020) used hydrogen peroxide to make mouse TM3 Leydig cells senescent and report that FOXO4-DRI caused p53 nuclear exclusion and apoptosis in those cells.4 In normal TM3 cells, where FOXO4 was low, they report that FOXO4-DRI "did not show significant toxicity".4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
80%
Typical dose
25–50 mg/dose
Route
SubQ
Time to peak
~0.5 h

Sources in this part

  1. 1Baar et al., 2017

The app lists a half-life of about 1 hour, 80% bioavailability by the subcutaneous route, a time to peak of about 0.5 hours and a duration of 12 hours, in a one-compartment model. The app's own note says these values are class-based estimates rather than measurements, and that no pharmacokinetic data have been published in any species. A search of PubMed for "FOXO4-DRI pharmacokinetics" returned one record, a 2026 review, and none of the primary papers read for this entry reports a plasma half-life, bioavailability or time to peak. Because no measured figure was identified in any of the papers read, there is nothing to set beside the app's figures here.

Baar and colleagues, using an antibody against the HIV-TAT sequence, report FOXO4-DRI "to be taken up as soon as 2-4h after administration and to remain detectable for at least 72h".1 This is intracellular detection in culture, not a blood concentration, and it is not a half-life.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureIn the sources read
Half-life~1 hNo measured value identified in any species
Bioavailability80%No measured value identified; the app lists the subcutaneous route, while Baar and colleagues dosed mice intravenously and, in comparison experiments, intraperitoneally1
Time to peak~0.5 hNo measured value identified
Duration12 hNo measured value identified; intracellular peptide was still detectable at 72 h in cultured cells1
4

Human studies

No controlled or uncontrolled trial in people was identified in PubMed or ClinicalTrials.gov for FOXO4-DRI. The app's own note makes the same statement and adds that the dose range it shows reflects publicly documented self-experiment reports, not clinical guidance.

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Baar and colleagues, Cell 20171In vitro human fibroblast experiments, then three mouse models: doxorubicin chemotoxicity, fast-aging XpdTTD/TTD and naturally agedNone; human IMR90 fibroblasts in culture, and mice3× i.v. at 5mg/kg every other day in the doxorubicin model; 30 days of treatment in kidney experiments111.73-fold viability difference, senescent against control IMR90; doxorubicin effects on weight and plasma AST neutralized; platelets not noticeably changed
Zhang and colleagues, Aging 20204Cell culture, then aged versus vehicle-injected miceNone; TM3 Leydig cells and naturally aged (20-24 months) male mice, n=65 mg/kg intraperitoneally every other day for three administrations; testing 30 days later4Serum testosterone higher after FOXO4-DRI in aged mice; no significant difference in body or testis weight
Huang and colleagues, Frontiers in Bioengineering and Biotechnology 20215Cell culture of expanded chondrocytesNone; chondrocytes from healthy donors25 μM in 2% FBS basal medium for 5 days; doses taken from an earlier study5Removed more than half of the cells at population doubling level 9, without significantly affecting level 3; no enhancement of chondrogenic potential; higher p16, p21 and p53 protein levels in cartilage grown from pretreated level 9 cells
Born and colleagues, Circulation 20236Mouse and rat models of pulmonary hypertension, with patient lung samples for senescence markersMice, rats and patient lung tissueNot stated in the record readPulmonary hemodynamic alterations and loss of lung endothelial cells in SM22-5-HTT+ mice given ABT263 or FOXO4-DRI, against controls
Bourgeois and colleagues, Nature Communications 20253NMR structural studyNoneNot applicableFOXO4-DRI binds the p53 transactivation domain and forms a transiently folded complex

Deeper analysis: Baar and colleagues, Cell 2017

Baar and colleagues reported the study in Cell in 2017, with the Department of Molecular Genetics at Erasmus University Medical Center Rotterdam, the Buck Institute for Research on Aging and the Medical University of Graz among the author affiliations, and Peter de Keizer as the last-listed author.1 The design had three parts: cultured human IMR90 fibroblasts made senescent by ionizing radiation or doxorubicin, then three mouse models, which the authors list as chemotoxicity, accelerated aging and natural aging.1 In culture, the peptide "potently and selectively (11.73 fold difference) reduce[d] the viability of senescent vs. control IMR90", and the authors report that the unrelated DRI peptide and the L-isoform of the same peptide did not affect senescent cell viability.1 A comparison compound, ABT-737, showed selectivity for senescent cells but "already at low doses it appeared to influence control cells as well".1 In the doxorubicin model, mice received doxorubicin 2× i.p. at 10mg/kg and FOXO4-DRI 3× i.v. at 5mg/kg every other day.1 The authors report that the doxorubicin effects on body weight were neutralized, and that FOXO4-DRI counteracted the doxorubicin-induced rise in plasma AST.1 When ganciclovir was used to clear senescent cells in the same reporter mice, the authors report that FOXO4-DRI "did not further enhance these effects".1

In the fast-aging XpdTTD/TTD model and in naturally aged mice, the authors report improved fur density and responsiveness, and lower plasma urea.1 Plasma urea percentages were quantified in pooled cohorts of "n=7–8 mice/treatment" after 30 days of treatment with vehicle or FOXO4-DRI.1 In naturally aged mice, plasma creatinine was also reduced by FOXO4-DRI.1 Among the null or limited results, the authors state that in naturally aged mice "The variation in running wheel activity was too large to perform meaningful experiments".1 They also report that FOXO4-DRI did not substantially change total body or kidney weight in the XpdTTD/TTD experiments.1 On safety, the authors write that the comparison senolytics ABT-263 and ABT-737 tend "to cause severe thrombocytopenia", whereas platelet levels 30 days after FOXO4-DRI were not noticeably influenced and the heart was not affected as far as tested.1 The authors' own caution is that "Though a more thorough analysis is required, as least as far as tested here FOXO4-DRI appears to be well tolerated".1 They also write that the peptide "has a strong preference for targeting high-SASP subpopulations of senescent cells, but it is unclear what causes heterogeneity in the SASP".1 Funding came from grants including NIH R37-AG009909 (to Judith Campisi) and the Austrian Science Fund, with Dutch Cancer Society and Dutch Kidney Foundation support to de Keizer and a colleague.1 On ties, the paper states that "Judith Campisi is co-founder and shareholder of Unity Pharmaceuticals" and that "Jan Hoeijmakers is co-founder of AgenD", adding that "Neither companies have been involved in this research, however".1 The paper's own statement does not mention Cleara; the later interview and 2025 structural paper described above show de Keizer's involvement with that company.2,3

Deeper analysis: Zhang and colleagues, Aging 2020

Zhang and colleagues reported that FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency in naturally aged mice.4 In testis tissue they report lower IL-1β, IL-6 and TGF-β, and no effect on IL-1α, IL-10 and TNF-α.4 The aged mice were 20 to 24 months old, received 5 mg/kg intraperitoneally every other day for three administrations, and were assessed 30 days later; the legend gives n=6.4 The authors write that there was "a lack of direct evidence showing that FOXO4-DRI can eliminate senescent Leydig cells in aged mice".4 They name two limitations: the mechanism of the testosterone rise was not elucidated, and "no attempt was made to assess when the increase in serum testosterone occurred or for how long the effect lasted".4 They also write that "special attention must be paid to muscle damage, especially cardiotoxicity" in treatment, noting that human FOXO4 protein is expressed in testis, placenta and muscle, and that "we could not address that issue in the present study".4 Funding was from the National Natural Science Foundation of China, and the authors declare "no conflicts of interest associated with this manuscript".4

Deeper analysis: Huang and colleagues, 2021, and Born and colleagues, 2023

Huang and colleagues (Frontiers in Bioengineering and Biotechnology, 2021) used chondrocytes from healthy donors expanded to population doubling level 9.5 They report that FOXO4-DRI removed more than half of the cells at level 9 without significantly affecting the cell number at level 3, and that pre-treatment "did not enhance the chondrogenic potential" of level 9 cells.5 In cartilage grown from pretreated level 9 cells they report higher p16, p21 and p53 protein levels, and write that "the potential adverse influence of senolytics needs to be further investigated".5 Their stated limitations include that "we only examined limited senolytics" and that they "used the doses that were reported in a previous study, which may not be optimal".5 Funding was from the Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, and the Albert B. Ferguson, Orthopaedic Fund of the Pittsburgh Foundation, and the authors report no commercial or financial relationships that could be construed as a conflict of interest.5

Born and colleagues (Circulation, 2023) list affiliations at INSERM and Hôpital Henri Mondor in Créteil, France, with co-authors in Belgium, the United Kingdom and elsewhere.6 They used FOXO4-DRI as one of several ways of eliminating senescent cells in pulmonary hypertension models, among them a suicide-gene construct and ABT263.6 They report pulmonary hemodynamic alterations and lung endothelial cell loss in mice overexpressing the serotonin transporter given either ABT263 or FOXO4-DRI, compared with controls, and conclude that "Elimination of senescent P-ECs by senolytic interventions may worsen pulmonary hemodynamics".6 The record read for this study lists a Medical Research Council grant (MC_U120085810) and does not include the full text, so the authors' own limitations and conflict statements are not reported here.

5

Doses reported in studies and on labels

No label for FOXO4-DRI was identified: a DailyMed search for "FOXO4-DRI" returned 0 labels. The app lists 25–50 mg/dose by the subcutaneous route and states that this range reflects publicly documented self-experiment reports, not clinical guidance. None of the papers read reports a dose in people, and the animal doses below are in mg/kg or micromolar concentrations, so they are not comparable to the app's mg per dose.

Table 5.1Doses reported in studies and on labels5 rows
SettingDose and routeDuration and nReference
Doxorubicin-exposed mice5 mg/kg intravenously, 3 doses every other day (days 1, 3, 5)Doxorubicin 2× i.p. at 10mg/kg; group size in figure legendsBaar and colleagues, 20171
XpdTTD/TTD mice, intraperitoneal comparison with ganciclovir3× 5mg/kg every other dayComparison with 5×25mg/kg/day ganciclovirBaar and colleagues, 20171
Naturally aged male mice5 mg/kg intraperitoneally every other day for three administrationsTesting 30 days later; n=6Zhang and colleagues, 20204
Cultured cells (live-imaging experiment)25μMCaspase-3/7 dye imaging in IR-senescent and control IMR90Baar and colleagues, 20171
HumansApp range 25–50 mg/dose SubQNo dose in people reported in the papers readThe app's figure

No adverse event data from people were identified. In mice, Baar and colleagues report no noticeable influence on platelet levels 30 days after treatment and no deleterious effects on the heart as far as tested, and they describe the peptide as "well tolerated" with the caution that a more thorough analysis is required.1 Zhang and colleagues found no significant difference in body or testis weight in treated aged mice, but write that muscle damage and cardiotoxicity need attention and that they could not address it.4 Born and colleagues report pulmonary hemodynamic alterations and loss of lung endothelial cells in one mouse strain given FOXO4-DRI or ABT263.6 In an interview, de Keizer said that the cell data show a roughly tenfold potency difference for senescent cells, and that if one in ten destroyed cells were a healthy cell, giving it to relatively healthy people would be, in his words, very risky.2 In the interview, dated July 16, 2018, he says the group was working on a version that is tenfold more selective, that the published paper describes version 3, and that the plan was to get version 4 to a hundredfold selectivity.2

7

Bloodwork and markers

The app lists a complete blood count, creatinine, eGFR, liver enzymes (ALT, AST), hs-CRP and LDH as markers to monitor. In the mouse work, Baar and colleagues measured platelet levels and other whole-blood values, plasma AST after doxorubicin, and plasma urea and creatinine as markers of renal function.1 Zhang and colleagues measured serum testosterone and testicular proteins, and flagged muscle damage and cardiotoxicity as issues to watch.4 The sources read give no human reference ranges or monitoring schedule for the peptide, and the app's marker list is the app's own.

8

Regulatory and anti-doping status

A DailyMed search for "FOXO4-DRI" returned 0 labels, and no other regulatory document for the peptide was identified. The 2026 WADA Prohibited List text read does not name FOXO4-DRI.7 Its S0 class is headed "S0 NON-APPROVED SUBSTANCES" and is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".7 The class covers any pharmacological substance that is not addressed by any of the subsequent sections of the List and has no current approval by any governmental regulatory health authority for human therapeutic use, with "drugs under pre-clinical or clinical development" given as an example.7 The list does not say whether FOXO4-DRI falls under S0, and the app describes it as sold strictly as a research chemical.7

No pharmacokinetic study in any species was identified, so the app's half-life, bioavailability, time to peak and duration remain estimates. No trial in people was identified, so no human efficacy, adverse event rate or dose range is available from the sources read. The founding paper's own wording is that "a more thorough analysis is required" on tolerability.1 The selectivity margin is about tenfold in cells (11.73-fold in the founding paper), and de Keizer says that with mice "we could scale it" but that for humans it is more difficult.1,2 The route used in the mouse studies (intravenous or intraperitoneal) differs from the subcutaneous route the app lists.1,4

What is the half-life of FOXO4-DRI?

The app lists about 1 hour, and the app's note describes this as a class-based estimate, not a measurement. None of the primary papers read reports a measured half-life in any species, so there is no measured figure to set beside the app's.

Has FOXO4-DRI been tested in humans?

No trial in people was identified in PubMed or ClinicalTrials.gov. The studies read used cultured cells, mice and a structural method.

What is FOXO4-DRI?

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4 interaction with p53 in senescent cells.1

How does FOXO4-DRI work?

Baar and colleagues report that it causes p53 nuclear exclusion and cell-intrinsic apoptosis in senescent cells.1 A 2025 NMR study reports that it binds the p53 transactivation domain and forms a transiently folded complex.3

How selective is FOXO4-DRI for senescent cells?

The founding paper reports an 11.73-fold viability difference between senescent and control IMR90 fibroblasts in culture.1 De Keizer describes the cell data as tenfold more potent against senescent cells and says that for relatively healthy people he finds the margin very risky.2

Has FOXO4-DRI been shown to raise testosterone?

Zhang and colleagues report higher serum testosterone in naturally aged male mice 30 days after three intraperitoneal doses, with n=6.4 The authors name as limitations that the mechanism was not elucidated and that duration of the effect was not assessed, and no human data were identified.4

What side effects has FOXO4-DRI caused?

No adverse event data from people were identified. In mice, Born and colleagues report pulmonary hemodynamic alterations and lung endothelial cell loss in one strain given FOXO4-DRI or ABT263, while Baar and colleagues report no noticeable influence on platelet levels.6,1

Is FOXO4-DRI banned by WADA?

The 2026 WADA Prohibited List text read does not name FOXO4-DRI.7 Its S0 class prohibits at all times any pharmacological substance that is not addressed by any of the subsequent sections of the List and has no current approval by any governmental regulatory health authority for human therapeutic use, and the list text read does not say whether FOXO4-DRI falls under it.7

Is FOXO4-DRI approved?

A DailyMed search for "FOXO4-DRI" returned 0 labels. The app describes it as sold strictly as a research chemical.

12

References

  1. Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 2017;169(1):132-147. PMID 28340339. PMID 28340339
  2. Lifespan Research Institute. Peter de Keizer on senolytics (interview). Web page. Lifespan interview
  3. Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun 2025;16:5672. PMID 40593617. PMID 40593617
  4. Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY) 2020. PMID 31959736. PMID 31959736
  5. Huang Y, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol 2021. PMID 33996787. PMID 33996787
  6. Born E, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation 2023;147(8):650-666. PMID 36515093. PMID 36515093
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list